

5th March, 2024

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to our earlier letter dated 12-Dec-23 on the Pre-Approval Inspection (PAI) conducted by USFDA at the Company's Oral-Oncology manufacturing facility situated in Bileshwarpura, Gujarat from 05-Dec-23 to 11-Dec-23.

In furtherance to the aforementioned intimation, this is to inform you that the USFDA has issued an Establishment Inspection Report ("EIR") for the said manufacturing facility and the inspection has now been successfully closed by the USFDA.

Please take the information on your records.

Thanking you,

Yours faithfully,

For, TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI
COMPANY SECRETARY

TORRENT PHARMACEUTICALS LIMITED

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com